In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Should We Use Echocardiography to Screen Young Athletes?

ESC Congress 2008 - Cardiac Screening Before Olympics?

Munich, Germany, Sunday 31 August 2008:

Studies conducted in Italy suggest that a pre-participation program, including echocardiography, is an efficient way to identify young athletes with cardiac disease.

Sudden and unexpected deaths in young competitive athletes are uncommon but highly visible events, which raise concern and ethical issues in both the lay public and medical community. Which is the best strategy to timely identify individuals with cardiac disease responsible for sudden death (primarily, HCM) is largely debated. Namely, the extent to which sophisticated testing, such as echocardiography, is needed is still undefined.

To address this question, we carried out an echocardiographic assessment of the structural cardiac diseases in a population of 4,450 athletes, initially judged free of cardiac disease and eligible for competition on the basis of pre-participation screening with 12-lead ECG.

None of the 4,450 athletes showed evidence of HCM. Other cardiac abnormalities were detected in only 12 athletes, including myocarditis (n=4), mitral valve prolapse (n=3), Marfan’s syndrome (n=2), aortic regurgitation with bicuspid valve (n=2), and arrhythmogenic right ventricular cardiomyopathy (n=1). In addition, 4 athletes were identified with borderline LV wall thickness (i.e., 13 mm) in the “gray-zone” between HCM and athlete’s heart. In 2 of these athletes, subsequent genetic analysis or clinical changes over an average 8-year follow-up resulted, respectively, in a diagnosis of HCM.

In Conclusion:

The pre-participation screening program including 12-lead ECG appears to be efficient in identifying young athletes with HCM, leading to their timely disqualification from competitive sports. These data also suggest that routine echocardiography is not an obligatory component of large population screening programs designed to identify young athletes with HCM.

Notes to editor

This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2008. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology.